The updated AHA/ACC dyslipidemia guideline broadens cardiovascular disease prevention beyond LDL‑C by emphasizing atherogenic particle burden, genetic risk from lipoprotein(a), and the PREVENT risk calculator – potentially improving health outcomes and enabling earlier, more precise risk stratification.
In March 2026, the American Heart Association (AHA) and the American College of Cardiology (ACC) issued an updated clinical guideline on the management of dyslipidemia.
Elevated LDL-C (low-density lipoprotein cholesterol), often called “bad cholesterol,” increases the risk of atherosclerotic cardiovascular disease (ASCVD). More recently, apolipoprotein B (apoB) – containing lipid particles – and, in particular, their genetically determined subset, lipoprotein(a) (Lp(a)) – have been recognized as strong predictors of cardiovascular (CV) event progression and recurrence. Although apoB and Lp(a) are independent risk factors, Lp(a) particles confer substantially higher per-particle CV risk than nonLp(a) apoB particles and may not respond to traditional lipid-lowering therapies such as statins.
While LDL-C remains widely used, contemporary risk assessment increasingly focuses on the burden of atherogenic particles, rather than LDL-C alone. Non-HDL cholesterol (non-HDL-C) is often preferred to LDL-C because it captures cholesterol carried by all atherogenic lipoproteins, and apoB provides an even more direct measure of atherogenic particle number.
Lipoprotein(a), or Lp(a), is an LDL-like particle in which apolipoprotein(a) is covalently bound to apoB. Lp(a) levels are largely genetically determined, making elevated Lp(a) one of the most common inherited dyslipidemias; approximately 20% of the population has high Lp(a). Elevated Lp(a) is associated with increased ASCVD risk across the risk spectrum, including higher possibility of recurrent events and a clear, approximately linear relationship with ASCVD events, a key consideration in primary prevention.
The new guideline emphasizes earlier intervention through healthy lifestyle behaviors (maintaining a healthy weight, regular physical activity, healthy sleep habits, and avoiding tobacco) and use of lipid-lowering medication when indicated. A major update is the recommendation to use a new risk calculator, PREVENT (Predicting Risk of Cardiovascular Disease EVENTs), for primary prevention of ASCVD. This calculator is designed for adults ages 30-79 years without known ASCVD or subclinical atherosclerosis and with LDL-C of 70-189 mg/dL. The tool estimates the risk of heart attack and stroke and helps guide treatment decisions, including lipid-lowering therapy such as statins and newer agents (e.g., PCSK9 inhibitors), alongside broader assessment of atherogenic lipoprotein burden (e.g., non–HDL-C and apoB) and other risk enhancers.
Additional recommendations include selective use of coronary artery calcium (CAC) scanning for men ages 40+ and women ages 45+ with borderline or intermediate 10-year ASCVD risk. The guideline also recommends measuring Lp(a) at least once during adulthood. Measurement of apoB in select individuals refines risk assessment and guide therapy, particularly among those with conditions such as metabolic syndrome, established CVD, diabetes, or elevated triglycerides – even after LDL-C and non-HDL-C goals are reached. Recommended LDL-C targets are <100 mg/dL for borderline/intermediate risk, <70 mg/dL for high risk, and <55 mg/dL for very high risk.
In summary, the updated AHA/ACC dyslipidemia guideline expands prevention beyond LDL-C alone by incorporating broader measures of atherogenic lipoprotein burden (non-HDL-C and apoB) and recognizing Lp(a) as an important genetic driver of ASCVD risk and residual risk. It also introduces the PREVENT risk calculator for primary prevention in adults ages 30-79 without known ASCVD to better inform diagnostic and therapeutic decisions.
For insurers, these updates underscore the value of earlier identification and more precise stratification of lipid-related risk, as well as access to evidence-based therapies that can reduce downstream morbidity, mortality, and cost – particularly within insured populations.
To learn how the latest medical breakthroughs and guidance can help you make better risk decisions, contact RGA.
